Imaging in CNS Drug Discovery and Development

Implications for Disease & Therapy

  • David Borsook
  • Lino R. Beccera
  • Edward Bullmore
  • Richard J. Hargreaves

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Background

    1. Front Matter
      Pages 1-1
    2. David Borsook, Edward Bullmore, Lino Becerra, Richard Hargreaves
      Pages 3-9
    3. Hong I. Wan, Mitchel A. Kling, Mark Day, Juan Chavez, Giora Feuerstein, Orest Hurko et al.
      Pages 11-28
  3. Imaging Approaches

    1. Front Matter
      Pages 30-30
    2. Natalie L. Voets
      Pages 31-45
    3. Dominique L. Jennings, A. Gregory Sorensen
      Pages 47-65
    4. Jaymin Upadhyay, David Borsook, Lino Becerra
      Pages 67-89
    5. Hanbing Lu, Thomas J. Ross, Elliot A. Stein
      Pages 91-104
    6. Elisenda Rodriguez, John W. Chen
      Pages 105-119
    7. Andrew P. Prescot, Perry F. Renshaw
      Pages 121-133
  4. Imaging CNS Drug Action

    1. Front Matter
      Pages 136-136
    2. Donald Williams, Alexandre Coimbra, Fuqiang Zhao
      Pages 137-151
    3. Ajay Verma, Ruben Declercq, Alexandre Coimbra, Eric Achten
      Pages 153-162
    4. Luana Colloca, Fabrizio Benedetti
      Pages 163-176
    5. Thomas Mueggler, Markus Rudin
      Pages 191-211
  5. Imaging CNS Disease States

    1. Front Matter
      Pages 214-214
    2. Markus von Kienlin, Céline Risterucci
      Pages 215-228
    3. Nicolau Beckmann, Catherine Cannet, Martin Rausch, Rainer Kneuer, Hans-Ulrich Gremlich
      Pages 229-250
    4. P. A. Woicik, N. Alia-Klein, N. D. Volkow, R. Z. Goldstein
      Pages 263-289
    5. David Goldman, Zhifeng Zhou
      Pages 291-301
    6. Bradford C. Dickerson
      Pages 303-318
    7. Damien A. Fair, Bradley L. Schlaggar
      Pages 319-338
    8. J. Douglas Bremner
      Pages 339-360
  6. Integrative Processes

    1. Front Matter
      Pages 362-362
    2. Igor D. Grachev, Richard J. Hargreaves
      Pages 363-379
    3. Richard Hargreaves, Edward Bullmore, Lino R. Becerra, David Borsook
      Pages 381-386
  7. Back Matter
    Pages 387-396

About this book


Imaging is a key area of translational research that provides a unique bridge from the laboratory to the clinic as the same techniques and technologies can applied across the various phases of drug development. Neuroimaging is now central to research and drug development in the neurosciences since it can be used to detect the pharmacological and physiological consequences of drug action within the living brain. Today neuroimaging is used primarily as a biomarker to help optimize our decision-making processes. Neuroimaging tools and technologies can be used to select drug candidates, confirm they engage their targets, link occupancy to biology and then, in a translational fashion, be used to help design the best clinical studies that truly test therapeutic hypotheses.

Topics covered include:

  • The role of imaging in drug development
  • Imaging approaches including structural, functional, molecular and chemical imaging
  • Imaging drug action including neuroreceptor mapping to examine drug occupancy characteristics, the involvement of specific neurotransmitter systems in CNS diseases and mechanisms of action
  • Functional mapping to provide pharmacodynamic evidence of central activity, "CNS fingerprinting" of the neuroanatomy of drug effects and disease drug interactions
  • Imaging disease states in preclinical and clinical domains

Neuroimaging today is all about the need to identify the best molecules, doses and hypotheses to advance into later stage long term extensive clinical trials that can often be confounded by high placebo response rates. Better decision making in early development allows resources to be focused on the drug candidates and therapeutic hypotheses that have the highest probability of success so that we can bring medical advances to patients as quickly as possible. Imaging in CNS Drug Discovery and Development was written by a group of preeminent international experts in the field of imaging.


Beverra CNS Hargreaves Imaging borsook development diagnosis disease drug implications magnetic resonance spectroscopy neuroimaging therapy

Editors and affiliations

  • David Borsook
    • 1
  • Lino R. Beccera
    • 2
  • Edward Bullmore
    • 3
  • Richard J. Hargreaves
    • 4
  1. 1.BelmontU.S.A.
  2. 2.BelmontU.S.A.
  3. 3.Dept. PsychiatryAddenbrooke's HospitalCambridgeUnited Kingdom
  4. 4.West PointU.S.A.

Bibliographic information